We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Specific nutritional supplement (Supportan®) in the supportive care of the radio-chemotherapy treatment of head and neck cancers: biochemical parameters. Preliminary study.
Endocrine, Metabolic & Immune Disorders Drug Targets 2013 December
BACKGROUND: This is a preliminary study of a specific nutritional supplement -Supportan(®) - for the clinical support of patients with locally advanced head and neck (H&N) cancers who underwent treatment with concurrent radiochemotherapy (RT-CHT).
MATERIAL AND METHODS: Seven patients received nutritional supplement (Supportan(®)) plus habitual diet during a median time of treatment with RT on 7.8 weeks plus concurrent weekly CHT(S). Specific serum protein fractions as a potential useful tool to evaluate the nutritional status were determined. The main objective was to assess the compliance with the above-mentioned treatment.
RESULTS: Patients completed the nutritional support, 5 / 7 patients via oral route and 2/7 patients through nasogastric tube. All studied patients, that completed treatment, had not severe mucositis -ulcera, hemrraghe and/ or infection. None of them had another severe toxicity by treatment nor had impairment of Pefomance Status. No differences in all specific sera proteins were observed between S and To.
CONCLUSION: In this preliminary study of few patients, we have observed a potential usefulness of Supportan(®) in the compliance of concurrent RT-CHT in patients with H&N cancers; moreover, its administration was useful to maintain the initial biochemical nutritional profile.
MATERIAL AND METHODS: Seven patients received nutritional supplement (Supportan(®)) plus habitual diet during a median time of treatment with RT on 7.8 weeks plus concurrent weekly CHT(S). Specific serum protein fractions as a potential useful tool to evaluate the nutritional status were determined. The main objective was to assess the compliance with the above-mentioned treatment.
RESULTS: Patients completed the nutritional support, 5 / 7 patients via oral route and 2/7 patients through nasogastric tube. All studied patients, that completed treatment, had not severe mucositis -ulcera, hemrraghe and/ or infection. None of them had another severe toxicity by treatment nor had impairment of Pefomance Status. No differences in all specific sera proteins were observed between S and To.
CONCLUSION: In this preliminary study of few patients, we have observed a potential usefulness of Supportan(®) in the compliance of concurrent RT-CHT in patients with H&N cancers; moreover, its administration was useful to maintain the initial biochemical nutritional profile.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app